SCHEMBL6448730

SCHEMBL6448730

CCC(N1CCC(c2ccccc2)CC1)[C@@]1(c2ccc(Cl)c(Cl)c2)CCCN(C(=O)c2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TACR2 P21452 10/20 0.47
TACR1 P25103 8/20 0.47
TACR3 P29371 7/20 0.47
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
CCR5 P51681 2/20 0.44
HSD11B1 P28845 5/20 0.41
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
CCR1 P32246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8593236 0.83 TACR3 (0.49) TACR2TACR1TACR3CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL6543493 0.81 TACR2 (0.46) TACR2TACR1TACR3CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL6544517 0.80 TACR2 (0.50) TACR2TACR1TACR3CYP3A4CYP2D6
SCHEMBL5677572 0.79 TACR2 (0.49) TACR2TACR1TACR3CYP3A4CYP2D6
SCHEMBL7678434 0.77 TACR2 (0.47) TACR2TACR1TACR3CYP3A4CYP2D6
SCHEMBL6699197 0.75 TACR2 (0.74) TACR2TACR1TACR3CYP3A4CYP2D6
SCHEMBL6699201 0.75 TACR2 (0.74) TACR2TACR1TACR3CYP3A4CYP2D6
SCHEMBL6448740 0.75 TACR2 (0.74) TACR2TACR1TACR3CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL6448448 0.74 TACR2 (0.73) TACR2TACR1TACR3CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL7086354 0.74 TACR2 (0.73) TACR2TACR1TACR3CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517708-A1 COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS Pfizer Products Inc. (US) 2005-03-30 EP disclosed
WO-2004000355-A1 COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-12-31 WO disclosed
EP-1192952-A2 Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist Pfizer Products Inc. (US) 2002-04-03 EP disclosed